Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.72 Million EUR | 69.06% |
| 2022 | -18.49 Million EUR | -0.57% |
| 2021 | -18.39 Million EUR | 26.07% |
| 2020 | -24.87 Million EUR | 16.04% |
| 2019 | -29.63 Million EUR | -14.43% |
| 2018 | -25.89 Million EUR | -32.98% |
| 2017 | -19.47 Million EUR | -317.52% |
| 2016 | -4.66 Million EUR | -280.08% |
| 2015 | 2.59 Million EUR | 117.29% |
| 2014 | -14.97 Million EUR | -47.31% |
| 2013 | -10.16 Million EUR | 49.46% |
| 2012 | -20.11 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -11.47 Million EUR | 0.0% |
| 2023 Q4 | -6.63 Million EUR | 0.0% |
| 2023 Q1 | 33.22 Million EUR | 270.57% |
| 2023 Q2 | -13.15 Million EUR | -139.61% |
| 2023 Q3 | -6.63 Million EUR | 49.56% |
| 2023 FY | -5.72 Million EUR | 69.06% |
| 2022 Q2 | -24.89 Million EUR | -211.07% |
| 2022 FY | -18.49 Million EUR | -0.57% |
| 2022 Q1 | 22.41 Million EUR | 221.88% |
| 2022 Q4 | -19.47 Million EUR | 0.0% |
| 2022 Q3 | -19.47 Million EUR | 21.77% |
| 2021 Q4 | -18.39 Million EUR | 4.61% |
| 2021 Q3 | -19.28 Million EUR | -9.53% |
| 2021 FY | -18.39 Million EUR | 26.07% |
| 2021 Q2 | -17.6 Million EUR | -158.62% |
| 2021 Q1 | 30.03 Million EUR | 220.72% |
| 2020 FY | -24.87 Million EUR | 16.04% |
| 2020 Q2 | -14.96 Million EUR | -127.37% |
| 2020 Q3 | -26.04 Million EUR | -74.02% |
| 2020 Q4 | -24.87 Million EUR | 4.46% |
| 2020 Q1 | 54.68 Million EUR | 283.81% |
| 2019 Q3 | -13.24 Million EUR | 28.39% |
| 2019 Q1 | -16.6 Million EUR | 37.54% |
| 2019 Q2 | -18.5 Million EUR | -11.43% |
| 2019 FY | -29.63 Million EUR | -14.43% |
| 2019 Q4 | -29.75 Million EUR | -124.55% |
| 2018 Q2 | -21.07 Million EUR | 19.76% |
| 2018 FY | -25.89 Million EUR | -32.98% |
| 2018 Q4 | -26.58 Million EUR | 0.09% |
| 2018 Q3 | -26.6 Million EUR | -26.22% |
| 2018 Q1 | -26.26 Million EUR | 1.52% |
| 2017 Q2 | -15.13 Million EUR | -55.03% |
| 2017 Q1 | -9.76 Million EUR | 31.7% |
| 2017 FY | -19.47 Million EUR | -317.52% |
| 2017 Q4 | -26.67 Million EUR | -69.67% |
| 2017 Q3 | -15.72 Million EUR | -3.9% |
| 2016 FY | -4.66 Million EUR | -280.08% |
| 2016 Q2 | -10.22 Million EUR | -30.9% |
| 2016 Q4 | -14.29 Million EUR | -174.46% |
| 2016 Q1 | -7.81 Million EUR | 4.85% |
| 2016 Q3 | -5.2 Million EUR | 49.09% |
| 2015 Q4 | -8.21 Million EUR | 83.63% |
| 2015 Q1 | -13.14 Million EUR | 12.23% |
| 2015 Q3 | -50.17 Million EUR | -433.1% |
| 2015 Q2 | -9.41 Million EUR | 28.41% |
| 2015 FY | 2.59 Million EUR | 117.29% |
| 2014 Q2 | -4.09 Million EUR | 43.26% |
| 2014 FY | -14.97 Million EUR | -47.31% |
| 2014 Q4 | -14.97 Million EUR | 10.26% |
| 2014 Q3 | -16.68 Million EUR | -307.35% |
| 2014 Q1 | -7.22 Million EUR | 28.97% |
| 2013 Q1 | -16.67 Million EUR | 17.09% |
| 2013 Q3 | -11.65 Million EUR | 22.09% |
| 2013 Q2 | -14.96 Million EUR | 10.29% |
| 2013 Q4 | -10.16 Million EUR | 12.78% |
| 2013 FY | -10.16 Million EUR | 49.46% |
| 2012 Q4 | -20.11 Million EUR | 9.58% |
| 2012 FY | -20.11 Million EUR | 0.0% |
| 2012 Q3 | -22.24 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 136.313% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 238.999% |
| SQZ Biotechnologies Company | -36.23 Million USD | 84.204% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 113.376% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 9.208% |
| Mesoblast Limited | 55.85 Million USD | 110.247% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 717.352% |
| Genus plc | 190.6 Million USD | 103.003% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 356.012% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 571.543% |
| Marizyme, Inc. | 18.56 Million USD | 130.826% |
| ContraFect Corporation | -6.02 Million USD | 5.012% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 941.765% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4351.368% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 595.4% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 355.281% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 204.037% |
| MultiCell Technologies, Inc. | 90.04 USD | 6357274.589% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -679.86% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 144.214% |
| EV Biologics, Inc. | 1.36 Million USD | 518.43% |
| Q BioMed Inc. | 4.06 Million USD | 240.985% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 118.734% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1019.719% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 668.017% |
| Biomind Labs Inc. | 711.4 Thousand USD | 904.608% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 105.213% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 144.696% |
| Skye Bioscience, Inc. | -5.72 Million USD | -0.046% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 765.395% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4194.303% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 201.339% |
| IMV Inc. | 7.67 Million USD | 174.623% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 28911.597% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 359.948% |
| GB Sciences, Inc. | 1.74 Million USD | 427.588% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3014.458% |
| HST Global, Inc. | 96.79 Thousand USD | 6013.651% |
| CSL Limited | 10.52 Billion USD | 100.054% |
| Halberd Corporation | 144.72 Thousand USD | 4055.197% |
| Enzolytics Inc. | 981.65 Thousand USD | 683.096% |
| Resverlogix Corp. | 6.45 Million USD | 188.73% |
| Affymax, Inc. | -5.59 Million USD | -2.269% |
| SYBLEU INC | 473.71 Thousand USD | 1308.324% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -750.408% |
| argenx SE | -2.02 Billion USD | 99.718% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 113.179% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 87.824% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 311.326% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 35.248% |
| AVAX Technologies, Inc. | -5.9 Million USD | 3.036% |
| Zenith Capital Corp. | 10.06 Thousand USD | 56975.994% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.461% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2955.831% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 339.896% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3579.445% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 109.454% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 386.287% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -122.721% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1691.282% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 128.23% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -31147.953% |
| BioStem Technologies, Inc. | 4.47 Million USD | 227.996% |
| ONE Bio Corp. | 9.04 Million USD | 163.318% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2944.167% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -436846.565% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2875.717% |
| Agentix Corp. | 37.63 Thousand USD | 15310.863% |
| LadRx Corporation | -2.03 Million USD | -181.075% |
| Cell Source, Inc. | 9.23 Million USD | 162.002% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -27947.824% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1001.18% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1001.18% |
| NovAccess Global Inc. | 2.17 Million USD | 362.754% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 180.951% |
| Itoco Inc. | 228.3 Thousand USD | 2607.172% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4309.164% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 215.473% |
| Kadimastem Ltd | -253.1 Thousand USD | -2161.539% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1524.416% |
| CytoDyn Inc. | 20.26 Million USD | 128.25% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -884598.609% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1282.078% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -61658.632% |
| Qrons Inc. | 351.42 Thousand USD | 1728.788% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 174.28% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2193.085% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1976.721% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 228.427% |
| International Stem Cell Corporation | 2.59 Million USD | 321.004% |
| Bioxytran, Inc. | 1.89 Million USD | 401.435% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9271.166% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 362.46% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 266.686% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 166.924% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 840.868% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -357.92% |
| Neutra Corp. | 52.18 Thousand USD | 11068.249% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -129.972% |
| PureTech Health plc | -167.19 Million USD | 96.576% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2237.204% |
| IXICO plc | -4.44 Million USD | -28.786% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 143.301% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 110.436% |
| CSL Limited | 10.52 Billion USD | 100.054% |
| Cellectis S.A. | -43.81 Million USD | 86.937% |